Rahul Mahajan MD FRCP (Edinburgh)Additional Professor, Department of Dermatology, Venereology and Leprosy, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaMaitreyee Panda MDProfessor, Department of Dermatology, Venereology and Leprosy, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, IndiaNibedita Patro MDProfessor, Department of Dermatology, Venereology and Leprosy, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India

• 1. Corticosteroids2. Methotrexate3. Azathioprine4. Mycophenolate Mofetil5. Calcineurin Inhibitors (Cyclosporine, Tacrolimus, Pimecrolimus)6. mTOR Inhibitors (Rapamycin/Sirolimus)7. Intravenous Immunoglobulins8. Anti-CD20 Monoclonal Antibody (Rituximab)9. Tumor Necrosis Factor-alpha Inhibitors (Etanercept, Infliximab, Adalimumab, and Certolizumab Pegol)10. Anti-interleukin-17 Monoclonal Antibodies (Secukinumab and Ixekizumab)11. Anti-interleukin-4/13 Monoclonal Antibody (Dupilumab)a12. Anti-interleukin-12/23 Monoclonal Antibodies (Ustekinumab)13. Anti-interleukin-1 Monoclonal Antibodies (Anakinra and Canakinumab)14. Anti-immunoglobulin E Monoclonal Antibody (Omalizumab and Others)15. Anti-B-cell Activating Factor Antibodies (Belimumab)16. Drug Under Trial for Psoriasis in Children17. Drugs Under Trial for Atopic Dermatitis in Children18. Phosphodiesterase-4 Inhibitors (Apremilast, Roflumilast, and Crisaborole)19. Janus Kinase Inhibitors20. Imiquimod and ResiquimodIndex